GlassScriptPhysician profile
Crystal Thornton
NPI 1932339215
$6,139.67
in general payments reported to CMS, 2019-2025
29 companies · $1,157 in 2025
The $1,157 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $465 · 2022: $971 · 2023: $1,276 · 2024: $2,271 · 2025: $1,157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,495 · Education: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,495.39 |
| Education | $208.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,211.55 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $927.44 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $545.58 | 2022-2025 | Tremfya |
| Genzyme Corporation | $469.73 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $395.40 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $339.01 | 2022-2023 | Vtama |
| Lilly USA, LLC | $282.71 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $260.19 | 2021-2025 | Oracea, Aklief, Epsolay |
| Ucb, INC. | $217.94 | 2023-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $195.34 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $162.15 | 2024-2025 | Dupixent |
| Journey Medical Corporation | $149.57 | 2022-2025 | |
| Almirall LLC | $130.69 | 2022-2025 | Klisyri, Seysara |
| Amgen INC. | $126.60 | 2022-2025 | Otezla, Otezla |
| Incyte Corporation | $121.04 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $114.43 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $110.42 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $57.66 | 2022-2023 | |
| Organon LLC | $53.88 | 2025 | Vtama |
| Leo Pharma INC. | $52.61 | 2022-2024 | Adbry |
| Biofrontera INC. | $52.10 | 2022-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Botanix Sb INC | $44.80 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $22.14 | 2025 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.68 | 2022 | |
| Lnhc, INC | $18.67 | 2025 | Zelsuvmi |
| Vyne Pharmaceuticals INC. | $18.21 | 2021 | |
| Sebela Pharmaceuticals INC. | $12.85 | 2022 | |
| Epi Health, LLC | $12.76 | 2022 | |
| Mission Pharmacal Company | $12.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Thornton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.